Brooks Laboratories FY26: A ₹24.58 Cr Profit Where the Pharma Business Made ₹7 Cr of It

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

After five straight years of losses, Brooks Laboratories closed FY26 with a net profit of ₹24.58 crore against a ₹9.97 crore loss the year before. The EPS line flipped from ₹-3.38 to ₹8.34. On the face of it, a clean turnaround.

The detail underneath complicates the headline. Operating profit for the year was about ₹7 crore on sales of ₹85.74 crore — the first positive operating figure since FY21, but a small one. Sitting beside it is Other Income of ₹19.95 crore, of which ₹18.78 crore is Brooks’s share of profit from its jointly controlled entity, Brooks Steriscience Limited. So the operating pharma business contributed roughly ₹7 crore; the associate stake contributed most of the rest.

Revenue grew 3.85%, from ₹82.56 crore to ₹85.74 crore. ROCE swung to 21.5% from negative territory. The market currently pays about 8.4x earnings here, against a peer median of 34x — a gap that exists partly because the earnings doing the dividing arrived through an associate rather than the factory.

A profit can be entirely real and still tell you almost nothing about the operation that bears the company’s name. The rest of this entry separates the two. Where did ₹24.58 crore actually come from?

2. Introduction

Incorporated in 2002, Brooks Laboratories is a contract manufacturer of pharmaceutical formulations, run from a plant at Baddi in Himachal Pradesh. The range covers liquid injection vials, dry powder injections, carbapenem injectables, tablets and oral suspensions, with applications across antibacterial, antibiotic, anti-gastric, anti-malarial and life-saving therapeutic segments. Around 90% of revenue comes from the domestic market, with exports to Afghanistan, Malaysia, Dubai, Benin and Congo; roughly 20% of revenue is sold under the company’s own brand.

The recent history runs through one structural fact. A loss-making Vadodara unit was transferred into joint venture Brooks Steriscience Limited on a slump-exchange basis in March 2021, after which Brooks turned profitable in FY22. FY23 then slid back into a ₹20.89 crore loss. The years since have been a slow climb back toward operating breakeven.

FY26 also carried a set of corporate events: a CEO appointment, an abandoned diversification plan, an upgraded credit rating, and — after year-end — a partial sale of the very Steriscience stake that now drives the consolidated profit. Section 6 takes those one at a time.

A reminder before the numbers: figures here are consolidated, in ₹ crore, and consolidation is the whole point at this company — it is the line that pulls the associate’s profit onto Brooks’s page.

3. Business Model: WTF Do They Even Do?

Brooks makes drugs for other people. It is a contract and loan-licence manufacturer, plus a modest own-brand and trading operation, reporting through two segments: Manufacturing and Trading.

The segment split is almost comic in its lopsidedness. Manufacturing booked ₹82.87 crore of FY26 revenue and a ₹6.94 crore segment result. Trading booked ₹2.87 crore of revenue and lost ₹0.06 crore — a business that, at this scale, mostly exists to remind the manufacturing segment how good it has things.

The installed capacity is genuinely large for a company this size: 2.30 crore liquid injection vials, 13.82 crore tablets, 2.01 crore dry-syrup units, 5.76 crore ampoules, 2.30 crore eye/ear drop units and 5.19 crore dry-powder injection units a year. The constraint has never been the machinery. It has been filling it profitably — sales have compounded at just 2.11% over five years while the plant stood ready for much more.

That is the recurring tension in a tender-and-contract pharma model: you win volume by being the cheapest credible bidder, which means margin lives or dies on raw-material costs you don’t control. FY23’s losses came down to API price volatility; the years since have been about clawing input costs back. The factory is fine. The economics of who gets to keep the value are the question.

A plant running below its profitable capacity is the most expensive kind of idle — it costs depreciation every year while you wait for the order book to grow into it.

4. Financials Overview

Figures are consolidated, in ₹ crore.

Three of these four lines flipped sign in a single year, which would be a remarkable operating story if the PAT line were an operating line. It isn’t. Operating profit moved from roughly ₹-8 crore to ₹+7 crore — a real ₹15 crore swing at the level the factory controls. The remaining distance to ₹24.58 crore of PAT is carried by Other Income, dominated by the ₹18.78 crore associate profit share.

The audited consolidated statement makes the mechanics explicit: standalone profit before tax